AMRI, Glide Pharma Sign Mfg Pact
By

Glide Pharma, a development company focused on solid dose formulations of therapeutics and vaccines and non-invasive diagnostics based in Abingdon, Oxfordshire, UK, has selected AMRI to manufacture the company's solid dose injection (SDI) formulation of octreotide, for use in a human bioequivalence study to be conducted in the fourth quarter of 2015.

Under the terms of the manufacturing agreement, AMRI will install the clinical production line developed by Glide into its GMP facility and will produce sterile octreotide solid doses for clinical study. Glide's clinical trial, planned for later this year, is designed to confirm that the company's solid dose formulation has an equivalent pharmacokinetic profile to a currently marketed product Sandostatin (octreotide ). AMRI will produce the formulation at its facility in Glasgow, UK.

Glide's delivery system, the Glide SDI, is used in the parenteral administration of drugs, which uses a solid dose formulation delivered using the company's proprietary injector. Octreotide is Glide's lead pipeline program.

Source: Glide Pharma

Leave a Reply

Your email address will not be published. Required fields are marked *